In addition, small molecules that inhibit the acetylation of SREBP1C by inhibiting p300/CBP may be used to treat metabolic disorders, such as NAFLD, obesity, and T2DM. Here, CREBBP is linked to obesity due to melanocortin 4 receptor deficiency.